USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF LYMPHOID-SPECIFIC IMMUNOTOXINS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7865
Program Year/Program:
1988 / SBIR
Agency Tracking Number:
7865
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Inland Laboratorytories
2600 Stemmons Freeway Dallas, TX 75207
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1988
Title: DEVELOPMENT OF LYMPHOID-SPECIFIC IMMUNOTOXINS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE GOAL OF THE PROPOSED RESEARCH IS TO DEVELOP AN EXTENSIVEPANEL OF RICIN A CHAIN IMMUNOTOXINS WHICH ARE CYTOTOXIC AND SPECIFIC FOR SUBSETS OF HUMAN LYMPHOCYTES AND OTHER CELL TYPES OF IMMUNOLOGICAL IMPORTANCE SUCH AS GRANULOCYTES, MONOCYTES, AND ANTIGEN PRESENTING CELLS. THE SPECIFIC AIM OF THE RESEARCH IS TO PREPARE RICIN A CHAIN IMMUNOTOXINS WITH A PANEL OF SEVENTEEN MURINE ANTI-HUMAN MONOCLONAL ANTIBODIES, AND TO TEST THE CYTOTOXICITY OF THESE IMMUNOTOXINS ON HUMAN CELL LINES WHICH EXPRESS THE TARGET ANTIGENS. THE FIRST STEP WILL BE TO SCREEN THE MONOCLONAL ANTIBODIES FOR THEIR ABILITY TO MEDIATE CYTOTOXICITY USING AN INDIRECT IMMUNOTOXIN CYTOTOXICITY ASSAY IN WHICH A SECONDARY IMMUNOTOXIN, PREPARED WITH FAB FRAGMENTS OF ANTI-MOUSE IGG ANTIBODY AND RICIN A CHAIN, IS USED TO TREAT TARGET CELLS COATED WITH THE PRIMARY MONOCLONAL ANTIBODY. IMMUNOTOXINS WILL BE PREPARED WITH THE MONOCLONAL ANTIBODIES WHICH ARE CYTOTOXIC IN THE INDIRECT ASSAY BY CONJUGATION WITH RICIN A CHAIN USING THE HETEROBIFUNCTIONAL CROSSLINKER, N-SUCCINIMIDYL 3-(2-PYRDYLDITHIO) PROPIONATE. THESE IMMUNOTOXINS WILL BE TESTED IN DIRECT CYTOTOXICITY ASSAYS. BOTH DIRECT AND INDIRECT CYTOTOXICITY ASSAYS WILL BE PERFORMED WITH IN VITRO HUMAN CELL LINES. THE COMMERCIALAVAILABILITY OF THESE REAGENTS WILL PROVIDE BOTH BASIC AND CLINICAL RESEARCHERS WITH A SAFE, SIMPLE, AND MORE EFFECTIVEMETHOD THAN IS CURRENTLY AVAILABLE FOR ELIMINATING SUBPOPULATIONS OF CELLS IN VITRO. THE LONG TERM OBJECTIVE IS TO DEVELOP, AND MAKE COMMERCIALLY AVAILABLE, IMMUNOTOXINSWHICH CAN BE UTILIZED FOR SPECIFIC IN VIVO THERAPY OF HUMAN MALIGNANCY, AUTOIMMUNITY, ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) AND OTHER DISEASES.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Inland Laboratories
10125 Metropolitan Austin, TX 78758

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No